Abstract

BackgroundIn China, the pneumococcal conjugate vaccine (PCV7) and the pneumococcal polysaccharide vaccine (PPSV23) are not offered under the government’s Expanded Program on Immunization and are instead administered for a fee. PCV7 is more effective and covers more serotypes associated with invasive disease in children, but is also more expensive, than PPSV23. Because of their expense, there is concern that these vaccines, especially PCV7, have low uptake particularly among non-locals, migrants from outside of Shanghai. This paper characterizes the differential coverage of PCV7 and PPSV23 between locals and non-locals in Shanghai, and illustrates coverage trends over time.MethodsIn this retrospective cohort study, children born between 2005 and 2011 were sampled from the Shanghai Immunization Program Information System. Bivariate and multivariable analyses examined the relationships between demographic characteristics, residency status (non-locals vs locals), and vaccination coverage.ResultsPPSV23 coverage (29.8 %) among children over 2 years of age was higher than PCV7 coverage (10.1 %) for locals and non-locals. Uptake of PCV7 increased substantially after children were 2 years of age. Overall, non-local populations had higher PPSV23 coverage (OR: 1.34; 98 % CI: 1.22, 1.46) but lower PCV7 coverage (OR: 0.617, 98 % CI: 0.547, 0.695) than locals.ConclusionsThere is a need for increasing overall pneumococcal coverage in Shanghai children, particularly with the more effective PCV7 vaccine. Morbidity and mortality due to invasive pneumococcal disease for children <1 year of age are unlikely to be mitigated if the current age-related vaccination patterns are not improved.

Highlights

  • In China, the pneumococcal conjugate vaccine (PCV7) and the pneumococcal polysaccharide vaccine (PPSV23) are not offered under the government’s Expanded Program on Immunization and are instead administered for a fee

  • In a previous analysis of children

  • 10.1 % of children in the entire study sample were vaccinated with the first dose of 7-valent pneumococcal conjugate vaccine (PCV7), and 29.8 % of children had received the first dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23)

Read more

Summary

Introduction

In China, the pneumococcal conjugate vaccine (PCV7) and the pneumococcal polysaccharide vaccine (PPSV23) are not offered under the government’s Expanded Program on Immunization and are instead administered for a fee. The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been available in China since 1996 and has several drawbacks: it only elicits shortterm immunity, cannot be administered until 2 years of age, and has a lower efficacy ranging from 60 to 70 % at preventing IPD [3, 4]. The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to China in 2008, it was pulled off the market in 2015 because its import license expired [5] It protects against fewer serotypes, but has better efficacy (>90 %) [4], and it can be Boulton et al BMC Public Health (2016) 16:109 administered earlier, at 6 weeks of age [4]. This moves up the timeline of protection and represents a major advantage over the PPSV23 since the incidence rate of IPD is highest in children

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call